Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Etude Exploratoire randomisée Comparant le Traitement Par Gemtuzumab Ozogamicin /Cytarabine au Traitement Standard Par Idarubicine/Cytarabinechez Les Sujets âgés de 60 à 80 Ans et présentant Une LAM et un Caryotype Non défavorable

NCT02473146 is registered in ClinicalTrials.gov with Versailles Hospital as lead sponsor.

NCT NCT02473146
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02473146 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Etude Exploratoire randomisée Comparant le Traitement Par Gemtuzumab Ozogamicin /Cytarabine au Traitement Standard Par Idarubicine/Cytarabinechez Les Sujets âgés de 60 à 80 Ans et présentant Une LAM et un Caryotype Non défavorable
Lead sponsor
Versailles Hospital
Phase
Phase 2/3
Overall status
Completed
Start date
November 18, 2015
Completion date
September 7, 2023
Enrollment
225 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia